After the news that Novartis failed to secure an Indian patent for Glivec, the patenting woes of Western pharma in India seem to continue as Merck are denied interim relief in a patent case against Indian firm Glenmark Pharmaceuticals, reports the Economic Times.
According to the Economic Times, the Delhi High Court has dismissed Merck's interim application that Glenmark Pharmaceuticals be restrained from manufacturing and selling diabetic medication Zita and Zita-Met – generic versions of Merck's Januvia and Janumet. The main lawsuit, however, is still free to continue.
“MSD is extremely disappointed with the decision of denial of injunction by the Delhi High Court against Glenmark for patent violation of our drugs Januvia and Janumet,” a company spokesperson said in the Economic Times report, adding that “MSD is considering all options, including an appeal of the decision.”
According to The Wall Street Journal, Glenmark say that they have not infringed on the patents, saying that it respects patents laws and launched the drug "after due diligence and research".
Are you in favour of the ruling? Do you share the concern expressed by some that the patent laws in India lie too heavily in favour of generic medications and fail to protect intellectual property? Do you think that this case signals the need for a change in how multinational pharmaceutical companies operate in India?
Why not join our discussion on LinkedIn, or leave a comment below.
If you're interested in hearing more about market access, you might be interested in attending Market Access World USA, 23-24 October 2013.